Immutep gets FDA orphan drug status for cancer treatment Apr 15, 2026 08:00AM
Maxim Group Downgrades Immutep Limited (IMMP) to Hold Mar 13, 2026 12:54PM
Immutep discontinues lung cancer trial after futility analysis Mar 13, 2026 08:05AM
Citizens Downgrades Immutep Limited (IMMP) to Market Perform Mar 13, 2026 03:41AM
Baird Downgrades Immutep Limited (IMMP) to Neutral Mar 13, 2026 03:41AM


Feb 17, 2026 03:29AM Citizens Starts Immutep Limited (IMMP) at Market Outperform
Nov 3, 2025 08:02AM Immutep receives A$4.6 million R&D tax incentive from French government
Aug 5, 2025 08:01AM Immutep gets FDA feedback on head and neck cancer drug development
May 27, 2025 08:04AM Immutep's (IMMP) Efti with Radiotherapy & KEYTRUDA Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma
May 15, 2025 08:01AM Immutep (IMMP) Reports Efti with KEYTRUDA & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer
Nov 15, 2024 07:20AM Immutep Limited (IMMP) PT Raised to $7 at Baird
Sep 24, 2024 08:01AM Immutep (IMMP) Receives A$3.6M R&D Tax Incentive from French Government
Jul 22, 2024 08:07AM Immutep (IMMP) Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer
Jun 27, 2024 06:26AM Immutep Limited (IMMP) PT Lowered to $6 at Baird